CI994 (Tacedinaline) - HDAC Inhibitor. CAS# 112522-64-2 0420 1371/journal

1371/journal

with favorable oral absorption and pharmacokinetics

thereby interfering with a key step in the autophagic process

Destabilization of both β-catenin and Ras via targeting axin is a potential therapeutic strategy for treatment of CRC and other type cancers activated Wnt/β-catenin and Ras pathways

CI994 (Tacedinaline) - HDAC Inhibitor. CAS# 112522-64-2 0420 1371/journalCI994 (Tacedinaline), CAS No. 112522 64 2, is a potent, selective and orally active histone deacetylase (HDAC) inhibitor. It inhibits HDAC1 (IC50 ~0. 57 M), HDAC2 (IC50 ~0. 90 M) and HDAC3 (IC50 ~1. 2 M). It does not inhibit HDAC6 and HDAC8 (IC50 >100 M). CI994 mediates G1 cell cycle arrest, inhibits proliferation, and induces apoptosis in tumor cell lines. It has also demonstrated antitumor activity in several tumor models, including the chemo